Presentation is loading. Please wait.

Presentation is loading. Please wait.

ISTVAN PETAK, MD, PHD FOUNDER, SCIENTIFIC DIRECTOR TM.

Similar presentations


Presentation on theme: "ISTVAN PETAK, MD, PHD FOUNDER, SCIENTIFIC DIRECTOR TM."— Presentation transcript:

1 ISTVAN PETAK, MD, PHD FOUNDER, SCIENTIFIC DIRECTOR TM

2 7,6 MILLION 13,1 MILLION 1:4 GLOBOCAN 2008, WHO

3 G ROWTH FACTOR G ROWTH F ACTOR R ECEPTOR T YROSIN KINASES N UCLEUS M UTANT G ENE A F AULTY SIGNAL TRANSDUCTION PROTEIN C ANCER C ELL T ARGETED DRUG D IVISION WHICH ARE THE DRUGABLE GENE MUTATIONS?

4 USA Dr. ISTVAN PETAK Dr. RICHARD SCHWAB SWISS 1995 => 2002 STORY OF KPS (2003) BIOMEDICAL RESEARCHERS TRAINED IN THE USA AND SWISS

5 Schwab Richárd, Peták István, Pintér Ferenc….Kopper László, Kéri György, Pap Ákos J Clin Oncol Oct 20;23(30): STORY OF KPS (2004) FIRST MOLECULAR DIAGNOSTICS BASED TARGETED THERAPY OF A LUNG CANCER PATIENT

6 MOLECULAR DIAGNOSTIC LABORATORY

7 LCM (ZEISS-PALM) 100% MULTIPLEX XS-DX TM OPTIMIZED DIRECT PCR PATENTED TECHNOLOGY TO ANALYZE SMALL SAMPLES

8 28 db56 db EGFR EXON 21 L858R SUCCESSFUL DIAGNOSTICS IN 84 CELLS (ITALIAN PATIENT) SUCCESSFUL DIAGNOSTICS IN 84 CELLS (ITALIAN PATIENT) Response to therapy

9 INTERNATIONAL EXPANSION WITH THE SUPPORT OF VENTURE CAPITAL INVESTMENT IN 2012

10 1% of all genes 90% somatic mutations 20% germline mutations 10% show both somatic and germline mutations 500,000 MUTATIONS IN 460 CANCER GENES 460 CANCER GENES SANGER DATABASE

11 2010. Október dia AbbottAstra-Z GSKLillyMerckNovartisPfizerRocheWyeth EGFRxx VEGF/Rxx IGF/Rxxx cMETxxxx Multixxxxxx PI3K/mTORxxxxx RAFxxx MEKxx SRCxx CDK4/6x CHK1xx Aurorakinázxxx Eg5,kinezinx Tubulinxx PARPxxx BCL2x IAPx Survivinx HSP90xx Deacetilázx Endotelin xx  -szekretázxx MDM2x DKK1x 5  -reduktázx VDAx TARGETED THERAPIES IN PIPELINES

12 5000< CLINICAL TRIALS FOR BREAST CANCER (WWW.CLINICALTRIALS.GOV) MORE AND MORE BIOMARKER DRIVEN LOOKING FOR SMALL FRACTION OF PATIENTS

13 MOLECULAR TARGETS …50 CLINICAL PARAMETERS ….

14 PIONEERING NEXT GENERATION SEQUENCING IN ONCOLOGY

15 „HeurAA” Heuristic Amplicon Analyzer PATENTED TECHNOLOGY TO FIND MUTATIONS IN MANY SEQUENCES PATENTED TECHNOLOGY TO FIND MUTATIONS IN MANY SEQUENCES

16 NUMBER OF GENES NUMBER

17 58 genes ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL.+ egyedi gének + FISH: EGFR, HER-2, FGFR, ALK, MET TARGETED RESEQUENCING PANELS Illumina HiSeq™ 2000 platform for 2574 exons representing 176 genes captured using Agilent SureSelect™ 50% acionable mutations MGH's Diagnostic Molecular Pathology lab SNaPshot assay, hotspot mutations in 14 oncogenes 50 to 60 patients per week NEXT: NGS 50 different targets Genomweb September 19, in combination with fluorescence in situ hybridization

18 MOLECULAR GENETICS BASED PERSONALIZED SIGNAL TRANSDUCTION THERAPIES GENE TEST CANCER CELLS 58< TARGET 280< TARGETED DRUGS

19 ONCOMPASS TM IS A “BLUE OCEAN” SERVICE IN A RAPIDLY GROWING MARKET OUR COSTUMERS: PATIENTS: THEY WANT ACCESS TO MORE EFFECTIVE AND LESS TOXIC TARGETED THERAPY PHARMA: THEY WANT TO FIND PATIENTS WITH RARE GENETIC PROFILE MATCHING THEIR DRUG PHARMA/CRO: THEY WANT TO RECRUIT PATIENTS WITH RARE GENETIC PROFILE TO ACCELERATE DOCTORS/HOSPITALS: THEY WANT MORE PATIENTS, CLINICAL TRIALS ARE PROFITABLE AND COMPETITIVE PAYERS/INSURANCE: THEY WANT MORE COST EFFECTIVE TREATMENT, THEY WANT MORE PATIENTS IN CLINICAL TRIALS

20 ONCOMPASS TM IS A “BLUE OCEAN” SERVICE IN A RAPIDLY GROWING MARKET IN THE NEXT 20 YEARS ENGINES OF GROWTH: PATIENTS: THE NUMBER WILL 2X IN THE NEXT 20 YEARS (INCREASE WILL BE FASTER IN ASIA) DRUGS: THE NUMBER OF TARGETED DRUGS WILL 10X GENES: NUMBER OF GENES ANALYZED ON ONE CHIP WILL 10X

21 THANK YOU FOR YOUR KIND ATTENTION!


Download ppt "ISTVAN PETAK, MD, PHD FOUNDER, SCIENTIFIC DIRECTOR TM."

Similar presentations


Ads by Google